$3.38
9.14% yesterday
Nasdaq, Nov 25, 10:01 pm CET
ISIN
US5894921072
Symbol
MREO
Sector
Industry

Mereo BioPharma Group plc Sponsored ADR Target price 2024 - Analyst rating & recommendation

Mereo BioPharma Group plc Sponsored ADR Classifications & Recommendation:

Buy
100%

Mereo BioPharma Group plc Sponsored ADR Price Target

Target Price $7.20
Price $3.38
Potential
Number of Estimates 5
5 Analysts have issued a price target Mereo BioPharma Group plc Sponsored ADR 2025 . The average Mereo BioPharma Group plc Sponsored ADR target price is $7.20. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 5 analysts: 5 Analysts recommend Mereo BioPharma Group plc Sponsored ADR to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Mereo BioPharma Group plc Sponsored ADR stock has an average upside potential 2025 of . Most analysts recommend the Mereo BioPharma Group plc Sponsored ADR stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Dec '23 2024
Estimates
Revenue Million $ 10.04 24.17
140.70%
Net Margin -306.29% -41.36%
86.50%

3 Analysts have issued a sales forecast Mereo BioPharma Group plc Sponsored ADR 2024 . The average Mereo BioPharma Group plc Sponsored ADR sales estimate is

$24.2m
Unlock
. This is
174.93% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$72.5m 724.80%
Unlock
, the lowest is
$0.0 100.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $10.0m
2024
$24.2m 140.70%
Unlock
2025
$19.9m 17.76%
Unlock
2026
$39.5m 98.49%
Unlock
2027
$24.4m 38.15%
Unlock
2028
$104m 324.18%
Unlock

2 Mereo BioPharma Group plc Sponsored ADR Analysts have issued a net profit forecast 2024. The average Mereo BioPharma Group plc Sponsored ADR net profit estimate is

$-10.0m
Unlock
. This is
74.01% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-9.2m 75.99%
Unlock
, the lowest is
$-10.8m 72.01%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-30.8m 42.86%
2024
$-10.0m 67.51%
Unlock
2025
$-8.5m 15.32%
Unlock
2026
$-12.3m 45.39%
Unlock
2027
$-12.3m 0.00%
Unlock
2028
$-4.6m 62.52%
Unlock

Net Margin

2023 -306.29%
2024
-41.36% 86.50%
Unlock
2025
-42.55% 2.88%
Unlock
2026
-31.18% 26.72%
Unlock
2027
-50.41% 61.67%
Unlock
2028
-4.46% 91.15%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Dec '23 2024
Estimates
Earnings Per Share $ -0.20 -0.07
42.86% 65.00%
P/E negative
EV/Sales 18.28

2 Analysts have issued a Mereo BioPharma Group plc Sponsored ADR forecast for earnings per share. The average Mereo BioPharma Group plc Sponsored ADR <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-0.07
Unlock
. This is
72.00% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-0.06 76.00%
Unlock
, the lowest is
$-0.07 72.00%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-0.20 42.86%
2024
$-0.07 65.00%
Unlock
2025
$-0.06 14.29%
Unlock
2026
$-0.08 33.33%
Unlock
2027
$-0.08 0.00%
Unlock
2028
$-0.03 62.50%
Unlock

P/E ratio

Current -13.52 57.21%
2024
-52.00 284.62%
Unlock
2025
-61.45 18.17%
Unlock
2026
-42.25 31.24%
Unlock
2027
-42.25 0.00%
Unlock
2028
-112.67 166.67%
Unlock

Based on analysts' sales estimates for 2024, the Mereo BioPharma Group plc Sponsored ADR stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

18.28
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
21.64
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 50.25 88.48%
2024
18.28 63.62%
Unlock
2025
22.23 21.59%
Unlock
2026
11.20 49.62%
Unlock
2027
18.10 61.68%
Unlock
2028
4.27 76.43%
Unlock

P/S ratio

Current 59.50 89.46%
2024
21.64 63.63%
Unlock
2025
26.31 21.59%
Unlock
2026
13.26 49.62%
Unlock
2027
21.43 61.68%
Unlock
2028
5.05 76.43%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today